Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 8/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692152 | 0.94 | RNASEL (0.57) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL20691346 | 0.94 | NT5E (0.49) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL24258560 | 0.88 | NT5E (0.43) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL24679777 | 0.83 | RNASEL (0.57) | RNASELNT5EP2RY1 | |
| SCHEMBL20691954 | 0.83 | NT5E (0.51) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL24680655 | 0.83 | NT5E (0.40) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL26201920 | 0.82 | RNASEL (0.63) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL22080505 | 0.82 | NT5E (0.53) | RNASELNT5EP2RY1SRCP2RY2 | |
| SCHEMBL22080123 | 0.82 | NT5E (0.51) | NT5EP2RY1SRCP2RY2P2RX1 | |
| SCHEMBL22080502 | 0.82 | RNASEL (0.57) | RNASELNT5EP2RY1SRCP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | RNASEL 662/4885NT5E 102/4885P2RY1 1124/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | RNASEL 662/4885NT5E 102/4885P2RY1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.